Propecia is a prescription medicine for male pattern hair loss in adult men. Its active ingredient, finasteride, lowers scalp DHT to help slow follicle shrinkage and preserve hair.
Propecia is a prescription oral tablet containing finasteride for adult men with androgenetic alopecia, also called male pattern hair loss. It lowers scalp dihydrotestosterone (DHT), helping slow follicle shrinkage and support long-term hair retention. Visible improvement usually requires several months of continuous treatment. The dose is stated on the pack — follow the leaflet.
Propecia contains finasteride, a selective 5-alpha-reductase type II inhibitor. The dose is stated on the pack — follow the leaflet. Higher-dose finasteride formulations are used for prostate conditions and are not interchangeable with Propecia for androgenetic alopecia.
The standard Propecia regimen for adult male pattern hair loss is one tablet taken orally once daily. It may be taken with or without food. Treatment is continuous because the DHT-lowering effect supports hair retention only while finasteride is being taken.
Swallow the tablet whole with water. Do not take two tablets to compensate for a missed dose. If a dose is forgotten, take the next scheduled dose at the usual time unless a prescriber has provided different instructions.
Finasteride does not provide an immediate cosmetic effect. Stopping treatment allows DHT activity to return toward its previous level, and the hair maintained by treatment may be lost progressively during the following months.
Testosterone is converted into DHT by the enzyme 5-alpha-reductase type II. Finasteride inhibits this enzyme, reducing DHT exposure in the scalp. Lower DHT levels can slow follicle shrinkage and help preserve existing scalp hair in genetically sensitive follicles.
It is designed for adult men with male pattern hair loss, where inherited sensitivity to DHT gradually causes follicle miniaturisation, shorter growth cycles, and progressive hair thinning.
Propecia is intended for adult men with male pattern hair loss.
Medical treatment for male pattern hair loss can target different biological pathways. Propecia lowers DHT through systemic enzyme inhibition, while topical minoxidil acts locally on hair follicles through a different mechanism.
| Approach | Main mechanism and use |
|---|---|
| Propecia, finasteride 1 mg | Oral reduction of DHT formation; supports hair retention and may improve scalp density in adult men |
| Topical minoxidil | Local follicle stimulation; applied to the scalp and used for pattern hair loss |
| Combined medical treatment | Two mechanisms used together when a prescriber considers the potential benefit greater than the added treatment burden |
Finasteride targets the hormonal pathway involved in follicle miniaturisation. Topical minoxidil does not lower DHT; it is used on the scalp to promote or prolong the growth phase of susceptible follicles.
Topical minoxidil can cause scalp irritation, dryness, unwanted facial hair, or an early increase in shedding. Finasteride has a different safety profile, including possible sexual adverse effects and effects on PSA interpretation. The choice depends on treatment goals, medical history, tolerance, and willingness to use a daily oral tablet or topical product.
Combination treatment is sometimes considered in clinical practice, although adding a second treatment does not guarantee a proportionally larger cosmetic result. A clinician may also investigate another cause when hair loss is sudden, diffuse, painful, inflamed, or associated with scaling.
Women who are pregnant or could become pregnant must not handle crushed or broken tablets. Finasteride can be absorbed through the skin and may interfere with the development of male external genitalia in a male fetus. Intact tablets have a protective coating, but damaged tablets require special handling.
Men with liver disease should provide that history before treatment because finasteride is metabolised in the liver.
Propecia is NOT for you if you are not an adult man with a clinician-confirmed pattern of androgenetic alopecia, or if you have unexplained hair loss, a serious finasteride allergy, or another finasteride product in your regimen.
Finasteride should not be shared with another person. It is not appropriate for female pattern hair loss, and it is not a treatment for every type of alopecia.
Finasteride is tolerated by many men, yet sexual adverse effects are clinically relevant. In controlled trials of Propecia, drug-related sexual adverse events were reported in a small minority of men and included decreased libido, erectile dysfunction, and reduced ejaculate volume [1].
The product information for Propecia reported sexual adverse-event rates of approximately 3% during the first year in controlled studies, compared with approximately 2% for placebo. These events often improved during continued treatment or after stopping, although post-marketing reports have described persistent sexual symptoms in some men.
Possible adverse effects include:
The relationship between finasteride, mood, sexual symptoms, expectation, and underlying distress can be complex. A symptom should still be taken seriously even when several factors may contribute. Persistent sexual symptoms, breast changes, or significant mood changes warrant prompt clinical assessment.
Allergic reactions are uncommon but can include rash, itching, swelling of the lips or face, and difficulty breathing. Severe swelling or breathing difficulty requires urgent medical care.
Finasteride lowers serum PSA, a blood marker used in prostate assessment. The prescribing clinician must know that a man is taking Propecia before interpreting a PSA result. The measured value may need clinical adjustment or comparison with previous results.
This point matters during routine health checks, especially for men over 40 or men undergoing prostate evaluation. Finasteride does not remove the need for age-appropriate prostate assessment.
The European Medicines Agency has reviewed finasteride safety information concerning sexual dysfunction and mood changes, supporting clear patient counselling before treatment [2].
Several routine errors can make Propecia appear less useful than it is:
The 1 mg dose is specifically used for male pattern hair loss. Increasing the dose without clinical direction increases exposure without establishing a faster cosmetic response.
In clinical practice, doctors often set one expectation first: Propecia is a maintenance treatment, not a short course. The first useful outcome may be slower loss rather than dramatic regrowth.
A dermatologist will usually assess the distribution of thinning, family history, scalp findings, recent illness, medicines, and the speed of shedding. A receding hairline that changes rapidly, patchy bald areas, scalp inflammation, or eyebrow loss may point to a different diagnosis.
Prescribers also discuss sexual function and mood before treatment. This creates a clear baseline and makes later changes easier to interpret. Men with a history of depression, suicidal thoughts, or troublesome sexual dysfunction need a more individualised risk discussion.
Clinical guidance from the National Institute for Health and Care Excellence supports investigating alternative causes when hair loss does not follow a typical androgenetic pattern [3].
One practical point is often missed: hair recovery is easier to see at the crown than at the frontal hairline. A stable hairline can still represent a worthwhile result if surrounding density is preserved.
The FDA's 2014 product information describes clinical assessment over several months rather than immediate improvement. Many men need three to six months before reduced shedding or early thickening becomes noticeable, while a twelve-month assessment gives a more reliable view. Cochrane evidence supports continued treatment when the response is beneficial and tolerated. Hair maintained by finasteride may be lost after treatment stops.
Propecia does not permanently cure male pattern hair loss. The European Medicines Agency's 2017 safety information describes finasteride as a treatment that reduces the hormonal process contributing to androgenetic alopecia while it is used. It does not remove inherited follicle sensitivity to DHT. Continued treatment is needed to preserve the benefit. Hair loss commonly resumes progressively after discontinuation.
The FDA's 2014 clinical data show that finasteride can improve hair counts and appearance in some men with frontal and vertex hair loss. Results vary, and the crown often responds more visibly than the temples. Follicles that have been miniaturised for many years may respond less than recently affected follicles. A dermatologist can assess whether the pattern fits androgenetic alopecia.
The FDA's 2014 prescribing information reports reproductive adverse effects, including changes in ejaculate volume, and post-marketing reports include male infertility or poor semen quality in selected cases. These effects are not expected in every man and may improve after treatment changes. Men planning conception should discuss fertility history, semen concerns, and timing with a clinician. WHO reproductive-health principles support evaluating the individual rather than assuming the same risk for every patient.
The European Medicines Agency's 2017 safety information states that finasteride 1 mg is not indicated for women. Pregnant women or women who may become pregnant must avoid contact with crushed or broken tablets because finasteride exposure can affect development of male fetal genitalia. Intact tablets should not be handled by this group if the coating is damaged. Women with hair loss require a different clinical assessment and treatment plan.
Yes. The FDA's 2014 label explains that finasteride lowers serum PSA, which can affect interpretation during prostate screening. Tell the clinician and testing service that you take finasteride before a PSA test. A clinician may interpret the result using the patient’s treatment status and previous PSA values. The medicine does not eliminate the need for appropriate prostate evaluation.
The FDA's 2014 dosing instructions support returning to the normal daily schedule rather than taking extra tablets. Missing one dose does not require doubling the next dose. Taking additional tablets can increase exposure without producing faster hair growth. A fixed daily routine or reminder can reduce repeated missed doses.
Your order will be securely packed and shipped within 24 hours. This is exactly what your package will look like (images of an actual item sent). It has the size and look of a regular private letter (24x11x0.7 cm) and its contents cannot be seen.
The first few months were uneventful, and I nearly stopped because I could not see much change. At month six, the crown looked better in the same bathroom light. I still had some shedding, but it was less noticeable than before.
I noticed reduced libido during the second month. It improved after I discussed it with my prescriber and stopped treatment. The experience was disappointing, but I was glad the symptom was taken seriously.
My hairline did not return, but the thinning at the crown seemed stable. I kept taking photographs every few months because day-to-day changes were impossible to judge.
I missed tablets during travel and took extra doses when I remembered. That made the routine confusing. Switching to one fixed daily time helped, although the cosmetic improvement remained modest.
